VitriVax raises $87M Series C to chase first Lyme disease vaccine
What's the deal? VitriVax, a Lyme disease vaccine developer, has raised an $87 million Series C, chief executive officer Romulo Colindres told Axios. There is no approved human Lyme vaccine, making the round a bet on a sizeable unmet need.
Why now? The financing is a sharp step-up from VitriVax's $17.25 million Series B in October 2025. It lands as the field's furthest-advanced rival — Pfizer and Valneva's candidate — faces regulatory uncertainty.
What's the endgame? VitriVax is working to bring a Lyme vaccine to market, competing with clinical-stage candidates from Pfizer and ModernaDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The Pfizer-Valneva candidate reported roughly 73% efficacy in Phase 3 in March 2026 but missed a prespecified statistical threshold after fewer cases than expected. Its application is now under European review, while US regulatory plans remain in discussion. The funding alone does not show how close VitriVax's candidate is to competing clinically.
The signal: A five-fold jump in financing within about a year reflects rising investor appetite for Lyme vaccines, a market still without an approved product.
Read more: Axios
Image credit: VitriVax